Intarcia Therapeutics, Inc. is a rapidly emerging biotech company driven by a "No Analog" mindset, dedicated to redesigning the treatment, prevention, and experience of chronic diseases. Founded in 1997, the company operates in the Biotechnology and Health Care industries, with its headquarters in the United States.
The company's commitment to seeking better outcomes and creating meaningful impact across business, health, and society is evident in its relentless pursuit of innovative solutions. Its cross-disciplinary teams, comprising forward-thinking scientists and entrepreneurs, operate in a fast-paced environment, continually pushing boundaries and unleashing fresh thinking.
Intarcia's latest investment, a Venture Round investment at 29 August 2019, was secured from GGV Capital. This signals investor confidence in the company's mission and potential to redefine the future of medicine.
Overall, Intarcia Therapeutics, Inc. presents an intriguing opportunity for venture capital firms seeking to invest in a company at the forefront of pioneering solutions in the biotech and healthcare sectors. With a strong focus on innovation and impact, the company is poised to continue making strides in improving the lives of individuals living with chronic diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $73.13M | - | 26 Feb 2019 | |
| Secondary Market | Unknown | 1 |
|
13 May 2017 |
| Debt Financing | $75.00M | 2 |
|
07 May 2016 |
| Venture Round | $225.00M | - | 27 Apr 2015 | |
| Venture Round | $200.00M | 6 |
|
01 Apr 2014 |
No recent news or press coverage available for Intarcia Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
